Home > Resources > Whitepapers > Rapid and affordable antimicrobial resistance profiling of tuberculosis samples

Rapid and affordable antimicrobial resistance profiling of tuberculosis samples

September 10, 2018

With over 10 million new cases worldwide each year and approximately 1.7 million deaths, tuberculosis (TB) is one of the leading global threats to human health. While disease detection and control methods have yielded a steady decline in the number of deaths attributable to TB, the emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis the predominant cause of TB is threatening to undermine this effort. Such strains are resistant to the most effective first-line drugs rifampicin and isoniazid and are associated with approximately 490,000 new cases of infection per annum1.

I'm For Real

Enter your details once to access all our information and resources

 

Spotlight

CHS Healthcare

Hospital discharge services We provide dedicated hospital discharge management services. We are the UK’s largest independent care brokers and our hospital discharge schemes are proven to significantly reduce delayed transfers of care (DTOC). Continuing healthcare services Our continuing healthcare services include a bespoke database, commissioned widely throughout England, and clinical services such as retrospective management and consultancy services.

OTHER WHITEPAPERS
news image

How Specialty Pharmacy Can Drive Better Outcomes in Cystic Fibrosis

whitePaper | June 28, 2022

CF is a rare, autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene that encodes the CFTR protein, an anion channel normally present in the epithelial membrane.1,2

Read More
news image

MEETING CURRENT AND FUTURE SERIALISATIONCHALLENGES

whitePaper | December 5, 2022

Serialisation has emerged as a complex challenge for the pharmaceuticals sector which is facing a multiplicity of differing regulations that vary from one country to another.

Read More
news image

Effects Of X-Ray Inspection On Pharmaceutical Products

whitePaper | December 12, 2019

X-ray inspection of pharmaceutical products and over-the-counter (OTC) medications are steadily increasing in use as pharmaceutical manufacturers worldwide strive to safeguard their brand reputations, protect consumers' welfare and comply with national and international regulations and legislation.

Read More
news image

The SwedishDrug Discovery and DevelopmentPipeline 2023

whitePaper | March 23, 2023

Sweden is and should remain a leading life sciences nation. The life sciences industry is one of Sweden’s economic base industries with a signifi cant share of our exports.

Read More
news image

Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

Read More
news image

Unlocking iPSCs to Improve CNS Modeling and Drug Discovery

whitePaper | June 15, 2022

To date, therapeutic advances in treating central nervous system (CNS) disorders have been incremental at best. As the global population increases and older demographics begin to make up a disproportionately larger percentage,

Read More

How Specialty Pharmacy Can Drive Better Outcomes in Cystic Fibrosis

whitePaper | June 28, 2022

CF is a rare, autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene that encodes the CFTR protein, an anion channel normally present in the epithelial membrane.1,2

Read More

MEETING CURRENT AND FUTURE SERIALISATIONCHALLENGES

whitePaper | December 5, 2022

Serialisation has emerged as a complex challenge for the pharmaceuticals sector which is facing a multiplicity of differing regulations that vary from one country to another.

Read More

Effects Of X-Ray Inspection On Pharmaceutical Products

whitePaper | December 12, 2019

X-ray inspection of pharmaceutical products and over-the-counter (OTC) medications are steadily increasing in use as pharmaceutical manufacturers worldwide strive to safeguard their brand reputations, protect consumers' welfare and comply with national and international regulations and legislation.

Read More

The SwedishDrug Discovery and DevelopmentPipeline 2023

whitePaper | March 23, 2023

Sweden is and should remain a leading life sciences nation. The life sciences industry is one of Sweden’s economic base industries with a signifi cant share of our exports.

Read More

Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

Read More

Unlocking iPSCs to Improve CNS Modeling and Drug Discovery

whitePaper | June 15, 2022

To date, therapeutic advances in treating central nervous system (CNS) disorders have been incremental at best. As the global population increases and older demographics begin to make up a disproportionately larger percentage, 

Read More
More Whitepapers

Spotlight

CHS Healthcare

Hospital discharge services We provide dedicated hospital discharge management services. We are the UK’s largest independent care brokers and our hospital discharge schemes are proven to significantly reduce delayed transfers of care (DTOC). Continuing healthcare services Our continuing healthcare services include a bespoke database, commissioned widely throughout England, and clinical services such as retrospective management and consultancy services.

Events

National Medtech & Biotech Summit 2024

Conference